UB VV310
Alternative Names: UB-VV310Latest Information Update: 20 Jun 2024
At a glance
- Originator Umoja Biopharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Non-Hodgkin's lymphoma
Most Recent Events
- 20 Jun 2024 Preclinical trials in Non-Hodgkin's lymphoma in USA (Parenteral) (Umoja Biopharma pipeline; June 2024)
- 03 Oct 2023 Preclinical trials in Autoimmune disorders in USA (Parenteral) prior to October 2023 (Umoja Biopharma pipeline, October 2023)
- 30 Nov 2020 Umoja Biopharma has patent pending for 'Viral vectors and packaging cell lines' in USA